Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.3.1411

Hepatitis B and C Seroprevalence in Solid Tumors - Necessity for Screening During Chemotherapy  

Oguz, Arzu (Baskent University, Medical Oncology Department)
Aykas, Fatma (Kayseri Education and Research Hospital, Internal Medicine Clinic)
Unal, Dilek (Kayseri Education and Research Hospital, Radiation Oncology Clinic)
Karahan, Samet (Kayseri Education and Research Hospital, Internal Medicine Clinic)
Uslu, Emine (Kayseri Education and Research Hospital, Internal Medicine Clinic)
Basak, Mustafa (Kayseri Education and Research Hospital, Internal Medicine Clinic)
Karaman, Ahmet (Kayseri Education and Research Hospital, Gastroenterology Clinic)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.3, 2014 , pp. 1411-1414 More about this Journal
Abstract
Background: Hepatitis B and C are the leading causes of liver diseases worldwide. For hematological and solid malignancy patients undergoing chemotherapy, increases in HBV DNA and HCV RNA levels can be detected which may result in reactivation and hepatitis-related morbidity and mortality. The aim of this study was to determine the seroprevalence of Hbs ag and Anti HCV positivity in patients with solid malignancies undergoing chemotherapy and consequences during follow-up. Materials and Methods: The files of 914 patients with solid malignancies whose hepatitis markers were determined serologically at diagnosis were reviewed retrospectively. All underwent adjuvant/palliative chemotherapy. For the cases with HBV and/or HCV positivity, HBV DNA and HCV RNA levels, liver function tests at diagnosis and during follow-up and the treatment modalities that were chosen were determined. Results: Of 914 cases, Hbs Ag, anti Hbs and anti HCV positivity were detected in 40 (4.4%), 336 (36.8%) and 26 (2.8%) of the cases respectively. All of the Hbs ag positive patients received prophylactic lamuvidine before the start of chemotherapy. In the Hbs ag and anti HCV positive cases, liver failure was not detected during chemotherapy and a delay in chemotherapy courses because of hepatitis was not encountered. Conclusions: Just as with hematological malignancies, screening for HBV and HCV should also be considered for patients with solid tumors undergoing chemotherapy. Prophylactic antiviral therapy for HBV reduces both the reactivation rates and HBV related mortality and morbidity. The clinical impact of HCV infection on patients undergoing chemotherapy is still not well characterized.
Keywords
Hepatitis B; hepatitis C; malignancy; lamuvidine;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Yeo W, Ho WM, Hui P, et al (2004). Use of lamuvidine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat, 88, 209-15.   DOI   ScienceOn
2 Yazici Y, Demir N, Cinarka H, Yilmaz H, Altintas N (2010). Seroprevalences of HBV, HCV and HIV among healthcare workers of Trabzon Chest Diseases Hospital. Turkish Bull Hyg Experiment Biol, 67, 27-32.
3 Yeo W, Chan PK, Zhong S, et al (2000). Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol, 62, 299-307.   DOI
4 Yeo W, Chan PK, Hui P, et al (2003). Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol, 70, 553-61.   DOI   ScienceOn
5 Yeo W, Johnson PJ (2006). Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 43, 209-20.   DOI   ScienceOn
6 Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM (1998). Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer, 83, 1224-30.   DOI
7 Persico M, De Marino F, Russo GD, et al (2002). Efficacy of lamuvidine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood, 99, 724-5.   DOI   ScienceOn
8 Soh LT, Ang PT, Sng I, Chua EJ, Ong YW (1992). Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer, 28, 1338-9.   DOI   ScienceOn
9 Mehmet D, Meliksah E, Serif Y, et al (2005). Prevalence of hepatitis B infection in the southeast region of Turkey: comparison of risk factors in rural and urban areas. Jpn J Infect Dis, 58, 15-9.
10 Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996). Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer, 78, 2210-5.   DOI
11 Steinberg JL, Yeo W, Zhong S, et al (2000). Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: procore/core mutations may play an important role. J Med Virol, 60, 249-55.   DOI
12 Utkan G, Azap A, Muallaoglu S, et al (2006). Hepatitis B and C in cancer patients: case-control study. Int J Hematol Oncol, 16, 103-7.
13 Uzun K, Alici S, Ozbay B, Gencer M, Irmak H (2002). The incidence of hepatitis C virus in patients with lung cancer. Turkish Respiratory J, 3, 91-3.
14 Vento S, Cainelli F, Mirandola F, et al (1996). Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet, 347, 92-3.   DOI   ScienceOn
15 Kohrt HE, Ouyang DL, Keeffe EB (2006). Systematic review: lamuvidine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther, 24, 1003-16.   DOI   ScienceOn
16 Kose S, Olmezoglu A, Gozaydin A, Ece G (2011). Seroprevalence of Hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr, 29, 652-5.
17 Hwang YY, Liang RH (2010). Hepatitis C in haematological patients. Hepat Res Treat, 2010, 961359.
18 Kanamori H, Fukawa H, Maruta A, et al (1992). Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci, 303, 109-11.   DOI   ScienceOn
19 Kumagai K, Takagi T, Nakamura S, et al (1997). Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol, 8, 107-9.   DOI   ScienceOn
20 Lau GK, Yiu HH, Fong DY, et al (2003). Early is superior to deferred preemptive lamuvidine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterol, 125, 1742-9.   DOI   ScienceOn
21 Lavanchy D (2004). Hepatitis B virus epidemiology, disaese burden, treatment and current and emerging prevention and control measures. J Viral Hepat, 11, 97-107.   DOI   ScienceOn
22 Long M, Jia W, Li S, et al (2011). A single center, prospective and randomized controlled study: Can the prophylactic use of lamuvidine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat, 127, 705-12.   DOI
23 Loomba R, Rowley A, Wesley R, et al (2008). Systematic review: the effect of preventive lamuvidine on Hepatitis B reactivation during chemotherapy. Ann Intern Med, 148, 519-28.   DOI   ScienceOn
24 Cainelli F, Longhi MS, Concia E, Vento S (2001). Failure of lamuvidine therapy for chemotherapy induced reactivation of hepatitis. Am J Gastroenterol, 96, 1651-2.   DOI
25 Besson C, Canioni D, Lepage E, et al (2006). Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol, 24, 953-60.   DOI   ScienceOn
26 Alagozlu H, Ozdemir O, Koksal B, Yilmaz A, Coskun M (2013). Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. Asian Pac J Cancer Prev, 14, 5489-94.   과학기술학회마을   DOI   ScienceOn
27 Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999). Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer, 81, 69-74.   DOI
28 Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN (1998). Successful treatment with lamuvidine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol, 9, 385-7.   DOI   ScienceOn
29 Custer B, Sullivan SD, Hazlet TK, et al (2004). Global epidemiology of hepatitis B virus. J Clin Gastroenterol, 38, 158-68.   DOI   ScienceOn
30 European Association for the Study of the Liver (2011). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol, 55, 245-64.   DOI   ScienceOn
31 Gurol E, Saban C, Oral O, Cigdem A, Armagan A (2006). Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol, 21, 299-305.   DOI
32 Arcaini L, Merli M, Passamonti F, et al (2010). Impact of treatment related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol, 85, 46-50.
33 Ter Borg F, Smorenburg S, de Man RA, et al (1998). Recovery from life threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamuvidine therapy. Dig Dis Sci, 43, 2267-70.   DOI   ScienceOn